Prestige Wealth Management Group LLC Decreases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Prestige Wealth Management Group LLC cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 29.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 316 shares of the biopharmaceutical company’s stock after selling 135 shares during the period. Prestige Wealth Management Group LLC’s holdings in Alnylam Pharmaceuticals were worth $74,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ALNY. Zions Bancorporation N.A. raised its stake in shares of Alnylam Pharmaceuticals by 13.5% in the fourth quarter. Zions Bancorporation N.A. now owns 672 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 80 shares during the period. TD Asset Management Inc. grew its holdings in Alnylam Pharmaceuticals by 3.2% during the 4th quarter. TD Asset Management Inc. now owns 504,038 shares of the biopharmaceutical company’s stock valued at $118,605,000 after purchasing an additional 15,755 shares during the last quarter. EFG Asset Management North America Corp. grew its holdings in Alnylam Pharmaceuticals by 29.3% during the 4th quarter. EFG Asset Management North America Corp. now owns 26,646 shares of the biopharmaceutical company’s stock valued at $6,276,000 after purchasing an additional 6,031 shares during the last quarter. EntryPoint Capital LLC raised its position in Alnylam Pharmaceuticals by 59.5% in the 4th quarter. EntryPoint Capital LLC now owns 2,542 shares of the biopharmaceutical company’s stock worth $598,000 after purchasing an additional 948 shares during the period. Finally, Crowley Wealth Management Inc. bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $294,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on ALNY. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Bank of America upped their price objective on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research report on Friday, March 21st. HC Wainwright lifted their target price on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. StockNews.com lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Finally, Sanford C. Bernstein reduced their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty have given a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $312.30.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock valued at $19,958,097 over the last 90 days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $280.96 on Wednesday. The stock’s 50-day moving average is $258.62 and its 200 day moving average is $260.26. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The company has a market cap of $36.37 billion, a P/E ratio of -129.47 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.